Citigroup | GenomeWeb


NEW YORK (GenomeWeb) – Citigroup this week initiated coverage of Cepheid with a Buy rating and a price target on its shares of $52.

NEW YORK (GenomeWeb News) – Citi Research analyst Amit Bhalla has increased his price target on Agilent Technologies' stock from $43 to $50 and has increased earnings-per-share estimates for the firm.

NEW YORK (GenomeWeb News) – Citigroup today initiated coverage of Agilent Technologies with a Buy rating and a $46 target on the company's stock.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Citigroup upgraded Life Technologies to Buy today following last week's contraction in the company's stock price.

Analyst Amit Bhalla said that trade-in revenue from customers who purchase the HiSeq 2000 platform would not be a "significant contributor," and trimmed total revenue estimates for the second quarter and full-year 2011.

The bank also placed a price target of $52 on Illumina's stock.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.